TRex Bio Filed for Initial Public Offering

The biotech firm seeks up to $133.3 million to accelerate development of therapies for inflammatory diseases.

Updated on Oct. 5, 2026 in Biotech

Isometric editorial illustration of a complex protein structure, representing immune regulatory pathway research in clinical immunology. — Biotech firm TRex Bio has filed for an initial public offering in the U.S., seeking to raise $133.3 million to advance its inflammatory disease research. AI Illustration. Upload story photo >

Live Poll

Is now a good time for you to invest in individual biotech stocks?

TRex Bio has officially filed registration paperwork for an initial public offering in the United States. The company intends to raise as much as $133.3 million to support its pipeline targeting autoimmune and inflammatory conditions.

Why it matters

This move signals a significant push to capitalize the company as it advances its clinical research programs for complex immune system disorders. It reflects the ongoing capital requirements for biotech firms operating in the high-cost sector of immunological drug development.

TRex Bio is marketing 8.3 million shares with an anticipated price range of $14 to $16 each. These figures represent the planned equity issuance compared to the company's prior private valuation and funding rounds.

The players

TRex Bio

A biotechnology company specializing in the development of therapeutic treatments for autoimmune and inflammatory diseases.

The details

TRex Bio functions as a biotechnology firm focused on the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company uses specialized research platforms to modulate immune regulatory pathways, which are the biological mechanisms that control how the body's defensive cells respond to threats. These pathways are critical in preventing the immune system from attacking healthy tissue, a failure that results in chronic inflammatory conditions.

The company filed the IPO registration document on Monday.

The Tech Race

This filing follows a pattern set by the broader market trend of biotech IPOs, where firms seek public capital to fund long-term clinical development cycles. The company is positioning itself to compete in the crowded landscape of immune-modulating therapeutics.

The public offering marks a transition in the company's operational capacity as it moves toward potential commercialization. Investors and industry stakeholders should monitor upcoming amendments to the filing to confirm final share pricing and market debut dates.

The takeaway

This filing confirms that TRex Bio is prepared to enter the public equity markets to fuel its drug pipeline. Observers should watch for the pricing of these 8.3 million shares, which will reveal investor sentiment regarding the company's research trajectory.